PPBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Purple Biotech Ltd (PPBT) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are mixed, with bearish moving averages and neutral RSI, while the MACD shows slight positive momentum. The options data shows no significant trading sentiment, and the financial performance indicates substantial losses with no revenue growth. While there is a positive catalyst in the form of a partnership with Converge Bio, the lack of strong trading signals, weak financials, and limited analyst enthusiasm make this stock a hold rather than a buy.
The MACD histogram is positive at 0.0587 and expanding, indicating slight bullish momentum. However, the RSI is neutral at 43.635, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 3.729, and resistance is at 4.226, with the stock trading near its pivot point of 3.978.
The partnership with Converge Bio to enhance the development of its tri-specific antibody platform is a positive development.
The company's financials show significant losses with no revenue growth. Analysts have lowered the price target from $34 to $30, and there is no recent congress trading data or significant insider/hedge fund activity.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$23.55M (up 5642.93% YoY), and an EPS of -0.01 (0% YoY). Gross margin remains at 0%.
H.C. Wainwright analyst Emily Bodnar maintains a Buy rating but lowered the price target from $34 to $30, citing a discounted cash flow analysis. The analyst highlights progress in preclinical CAPTN-3 programs and expects updates on investigational new drug submissions and Phase 1 plans throughout 2026.
